NOVEL METHOD FOR PREVENTING OR TREATING M TUBERCULOSIS INFECTION

• US 20190030154A1
• Filed: 09/19/2018
• Published: 01/31/2019
• Est. Priority Date: 04/29/2005
• Status: Active Grant

• Current Assignee: Glaxosmithkline Biologicals SA (GlaxoSmithKline PLC)
• Original Assignee: Glaxosmithkline Biologicals SA (GlaxoSmithKline PLC)
• Inventors: MARCHAND, Martine
• Granted Patent: US 10,350,283 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/523 expressing foreign proteins
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/55566 Emulsions, e.g. Freund's adjuvant, MF59
• CPC Class Codes: A61K 2039/55572 Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
• CPC Class Codes: A61K 2039/55577 Saponins; Quil A; QS21; ISCOMS
• CPC Class Codes: A61K 2039/575 humoral response
• CPC Class Codes: A61K 31/4409 only substituted in position 4, e.g. isoniazid, iproniazid
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 39/04 Mycobacterium, e.g. Mycobacterium tuberculosis
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 31/06 for tuberculosis
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/35 from Mycobacteriaceae (F)

Abstract

The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.

Claims

1-10. -10. (canceled)

11. A polynucleotide comprising a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:

4.

12. The polynucleotide according to claim 11, comprising the nucleic acid sequence of SEQ ID NO:

3.

13. A pharmaceutical composition comprising the polynucleotide according to claim 12.

14. The pharmaceutical composition according to claim 13, wherein the polynucleotide is provided in a viral vector.

15. The pharmaceutical composition according to claim 13, wherein the polynucleotide is provided in a bacterium host cell.

16. The pharmaceutical composition according to claim 15, wherein the bacterium is Bacillus Calmette-Guerin.